Utah Medical Products Inc. (UTMD)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 706698 · fiscal year ends in Dec
Closing price $68.33 on 30 Oct 2026; 52-week range $53.80 to $76.66.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $36.1M
- Revenue growth
- -7.0%
- Net income, last twelve months
- $10.5M
- Earnings per share
- $3.28
- Gross margin
- 57.9%
- Operating margin
- 28.4%
- Net margin
- 29.0%
- Free cash flow
- $11.4M
- Return on equity
- 8.6%
- Market value
- $217.5M
- Price to earnings
- 20.8x
- Cash
- $87.5M
- Debt
- $195.0K
- Debt to equity
- 0.00
- Shares outstanding
- 3.2M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $38.5M | $11.4M | $11.3M | $3.48 | $14.3M | 10-K filed 27 Mar 2026 |
| FY2024 | 31 Dec 2024 | $40.9M | $13.6M | $13.9M | $3.96 | $14.6M | 10-K filed 26 Mar 2025 |
| FY2023 | 31 Dec 2023 | $50.2M | $16.8M | $16.6M | $4.57 | $21.6M | 10-K filed 26 Mar 2024 |
| FY2022 | 31 Dec 2022 | $52.3M | $19.8M | $16.5M | $4.52 | $20.3M | 10-K filed 27 Mar 2023 |
| FY2021 | 31 Dec 2021 | $49.1M | $18.9M | $14.8M | $4.04 | $20.7M | 10-K filed 25 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $8.5M | $2.7M | $0.84 |
| Q1 FY2026 | 31 Mar 2026 | $8.7M | $2.6M | $0.82 |
| Q4 FY2025 | 31 Dec 2025 | $9.0M | $2.6M | $0.80 |
| Q3 FY2025 | 30 Sep 2025 | $9.8M | $2.6M | $0.82 |
| Q2 FY2025 | 30 Jun 2025 | $10.0M | $3.0M | $0.94 |
| Q1 FY2025 | 31 Mar 2025 | $9.7M | $3.0M | $0.92 |
| Q4 FY2024 | 31 Dec 2024 | $9.2M | $2.9M | $0.86 |
| Q3 FY2024 | 30 Sep 2024 | $10.0M | $3.6M | $1.02 |
Company events
The newest 8-K filings of 184 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 22 Oct 2026 | 8-K | Results | 2.02, 9.01 |
| 31 Aug 2026 | 8-K | Investor update | 7.01 |
| 23 Jul 2026 | 8-K | Results | 2.02, 9.01 |
| 4 May 2026 | 8-K | Shareholder vote | 5.07 |
| 23 Apr 2026 | 8-K | Results | 2.02, 9.01 |
| 29 Jan 2026 | 8-K | Results | 2.02, 9.01 |
| 4 Nov 2025 | 8-K | Leadership change, Other events | 5.02, 8.01, 9.01 |
| 23 Oct 2025 | 8-K | Results | 2.02, 9.01 |
| 24 Jul 2025 | 8-K | Results | 2.02, 9.01 |
| 5 May 2025 | 8-K | Shareholder vote | 5.07 |
| 29 Apr 2025 | 8-K | Results | 2.02, 9.01 |
| 28 Jan 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 488 held.
| Filed | Form | Period |
|---|---|---|
| 29 Oct 2026 | SC TO-I/A | – |
| 22 Oct 2026 | 8-K | 22 Oct 2026 |
| 5 Oct 2026 | SC TO-I/A | – |
| 29 Sep 2026 | SC TO-I/A | – |
| 25 Sep 2026 | SC TO-C | – |
| 24 Sep 2026 | SC TO-C | – |
| 24 Sep 2026 | SC TO-I | – |
| 17 Sep 2026 | SC TO-C | – |
| 31 Aug 2026 | 8-K | 31 Aug 2026 |
| 12 Aug 2026 | 10-Q | 30 Jun 2026 |
| 23 Jul 2026 | 8-K | 23 Jul 2026 |
| 27 May 2026 | SD | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 29 Oct 2026 | Cornwell Kevin L, Chairman, CEO | Purchase | 1,000 | $66.75 | $66.8K | 189,472 | 29 Oct 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | BRANDES INVESTMENT PARTNERS, LP | 13G amended | 14.9% | 475.2K |
| 13 Aug 2026 | Renaissance Technologies LLC | 13G amended | 5.52% | 175.8K |
| 14 May 2026 | BRANDES INVESTMENT PARTNERS, LP | 13G amended | 14.1% | 449.7K |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 140.2K | -7.7% | 3.58 |
| 30 Sep 2026 | 151.9K | -11.77% | 4.79 |
| 15 Sep 2026 | 172.2K | +3.22% | 4.53 |
| 31 Aug 2026 | 166.8K | +19.39% | 4.03 |
| 14 Aug 2026 | 139.7K | +3.05% | 7.04 |
| 31 Jul 2026 | 135.6K | -3.22% | 3.37 |
| 15 Jul 2026 | 140.1K | +1% | 7.72 |
| 30 Jun 2026 | 138.7K | +5.77% | 6.79 |
Funds that hold it
From each fund's latest Form 13F.
126 funds held it at 30 Jun 2026: 54 added and 34 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Brandes Investment Partners, LP | 475,158 | $32.8M | +25,879 |
| BlackRock, Inc. | 203,690 | $14.1M | +16,041 |
| Dimensional Fund Advisors LP | 198,817 | $13.7M | +909 |
| Renaissance Technologies LLC | 175,814 | $12.1M | -8,300 |
| Vanguard Capital Management LLC | 134,535 | $9.3M | -4,025 |
| Geode Capital Management, LLC | 108,048 | $7.5M | -12,049 |
| Minerva Advisors LLC | 93,615 | $6.5M | 0 |
| Hotchkis & Wiley Capital Management LLC | 85,231 | $5.9M | -3,900 |
| Rice Hall James & Associates, LLC | 71,363 | $4.9M | +3,481 |
| Morgan Stanley | 69,671 | $4.8M | +20,870 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B